Predictors and prognosis of early ischemic mitral regurgitation in the era of primary percutaneous coronary revascularisation

Table 4 Cumulative clinical outcomes according to early ischemic MR severity

Variable	All (n = 174; 100%)	No MR (n = 95; 55%)	Mild MR (n = 60; 34%)	Moderate or severe MR (n = 19; 11%)	P value
Death	2 (1%)	0 (0%)	1 (2%)	1 (5%)	0.13
Stroke	3 (2%)	2 (2%)	1 (2%)	0 (0%)	0.81
Re-infarction	13 (8%)	10 (11%)	2 (3%)	1 (5%)	0.23
Re-Hospitalization for CHF	2 (1%)	0 (0%)	1 (2%)	1 (5%)	0.13
Percutaneous coronary intervention	9 (5%)	6 (6%)	2 (3%)	1 (5%)	0.72
Coronary artery bypass grafting	14 (8%)	5 (6%)	4 (7%)	5 (26%)	0.008
Annuloplasty or mitral valve surgery	5 (3%)	0 (0%)	0 (0%)	5 (26%)	<0.0001
MACE*	33 (19%)	15 (16%)	10 (17%)	8 (42%)	0.02

*Major adverse cardiac events (MACE): defined as a combined endpoint of death, MI, stroke, re-hospitalization for congestive heart failure, PCI or CABG and mitral repair or replacement.
MR: Mitral Regurgitation; CHF: Congestive Heart Failure; MACE: Major Adverse Cardiovascular Event.

ISSN: 1476-7120